Kiora Pharmaceuticals (KPRX) Financials

Kiora Pharmaceuticals (NASDAQ: KPRX) continues to look like a classic clinical-stage biotech balance sheet story: plenty of cash on hand, but no product revenue and persistent operating losses. Over the last several quarters, the company has remained heavily dependent on investment income and balance sheet liquidity rather than commercial sales.

Top-line performance remains weak. In Q1 2026, Kiora reported zero revenue, versus the large revenue figure shown in Q1 2024, which appears to have been a one-time or non-recurring item. Since then, the business has operated with no recurring sales base.

Losses narrowed in Q1 2026 compared with Q4 2025. Net loss improved to $2.4 million from $6.5 million in the prior quarter. That said, the company is still unprofitable and continues to burn cash.

Operating expenses were lower in Q1 2026. Research and development expense was $2.1 million and SG&A was $1.6 million, both below Q4 2025 levels. For a development-stage biotech, that can indicate tighter spending, though it may also reflect timing of clinical and administrative costs.

Cash and investments improved meaningfully in the latest quarter. Kiora ended Q1 2026 with about $13.9 million in cash and short-term investments, up from roughly $19.4 million in Q3 2025 but down from the much higher levels seen in early 2024. The current liquidity position still gives the company some runway, but not a long-term cushion.

Operating cash burn remains elevated. Q1 2026 operating cash flow was a negative $3.2 million, compared with negative $2.2 million in Q4 2025. That suggests the company is still consuming cash at a rate that will matter to investors.

Investing cash flow was positive in Q1 2026. The company generated $5.4 million from investment sales, which helped offset operating burn and drove a positive net change in cash for the quarter. This is helpful for liquidity, but it is not a recurring operating source.

Balance sheet leverage is modest, but liabilities rose from earlier periods. Total liabilities were $7.3 million at March 31, 2026, while total equity was $13.9 million. That leaves the company with a net asset position, but equity has been volatile over the past year.

• Liquidity remains intact with more than $13 million in cash and short-term investments at the end of Q1 2026.
• Q1 2026 net loss improved versus Q4 2025, indicating some quarter-to-quarter expense relief.
• Operating expenses declined sequentially in both R&D and SG&A.
• Investment sales boosted cash and helped offset ongoing operating losses.
• No recurring revenue is visible in the latest quarter, so the investment case still depends on pipeline progress.
• Interest and investment income provided support, but this is not core operating revenue.
• Share count has moved around over time, which can be a sign of financing or restructuring activity.
• Operating cash flow remains negative at more than $3 million in Q1 2026.
• The company has not shown durable profitability across the recent four-year window.
• Historical results show volatility in both earnings and balance sheet line items, which raises execution risk.

Bottom line: Kiora Pharmaceuticals looks well-capitalized for a small biotech, but the financials still show a company in development mode rather than a self-sustaining business. Investors will likely need to focus on clinical progress and future financing needs more than near-term earnings power.